Dementia Drugs Market 2021-2027 Trends, Research Report, Growth Trends, Opportunities, Forecast to 2027

 

Dementia is an application of disease that affects the functioning of the brain causing decline in memory or other thinking skills. Alzheimer's disease is the most typical and largest type of dementia (in over 60% cases), that is observed among people aged 65 years and above. Accumulation of a protein called beta amyloid in the spaces between nerve cells because of genetic mutation is really a major cause of dementia. Although dementia isn't treatable, symptomatic treatment is followed in most cases. Research will be carried out to develop therapies devoted to the role of beta-amyloid in dementia.

Major factor fueling growth of the Dementia Drugs Market includes, increasing amount of drugs in the pipeline, which are likely to enter into the marketplace by 2020-2022. Based on the study published by Translational Research and Clinical Intervention, in September 2017, 105 new drugs have been in pipeline, out of which 25 have been in phase one, 52 in phase two, and 28 in phase three. These new products use novel approaches such as for example immunotherapy to a target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint efforts is also boosting growth of the market. As an example, in November 2017, Novartis and Amgen, combined with Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease.